Daniel R Quast
Overview
Explore the profile of Daniel R Quast including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
618
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Drews J, Zachaus M, Kleemann T, Schirra J, Cahyadi O, Moschler O, et al.
Gut
. 2025 Feb;
PMID: 39988360
Background: Prophylactic application of a haemostatic gel to the resection field may be an easy way to prevent delayed bleeding, a frequent complication after endoscopic mucosal resection (EMR). Objective: We...
2.
Charles James J, Schulze H, Siems N, Prehn C, Quast D, Trampe N, et al.
Sci Rep
. 2025 Jan;
15(1):1695.
PMID: 39799217
A substantial proportion of patients suffer from Post-COVID Syndrome (PCS) with fatigue and impairment of memory and concentration being the most important symptoms. We here set out to perform in-depth...
3.
Quast D, Xie C, Bound M, Grivell J, Hatzinikolas S, Jones K, et al.
Diabetes
. 2025 Jan;
PMID: 39761379
Individuals with type 2 diabetes are at high risk of postprandial falls in blood pressure (BP) (i.e., a reduction in systolic BP of ≥20mmHg, termed postprandial hypotension (PPH)), which increases...
4.
Jalleh R, Marathe C, Rayner C, Jones K, Umapathysivam M, Wu T, et al.
Endocrinology
. 2024 Nov;
166(1).
PMID: 39568409
Glucagon-like peptide-1 (GLP-1) receptor agonists and the dual GLP-1- and glucose-dependent insulinotropic polypeptide receptor co-agonist tirzepatide (referred to here collectively as "GLP-1-based therapy") are incretin-based therapies being used increasingly in...
5.
Jalleh R, Plummer M, Marathe C, Umapathysivam M, Quast D, Rayner C, et al.
J Clin Endocrinol Metab
. 2024 Oct;
110(1):1-15.
PMID: 39418085
Context: Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are established therapeutics for type 2 diabetes and obesity. Among other mechanisms, they slow gastric emptying and motility of the small intestine. This...
6.
Abu Rached N, Dietrich J, Ocker L, Quast D, Stockfleth E, Bechara F
J Dtsch Dermatol Ges
. 2024 Aug;
22(10):1427-1429.
PMID: 39106221
No abstract available.
7.
Quast D, Lancaster D, Xie C, Bound M, Grivell J, Jones K, et al.
Diabetes Obes Metab
. 2024 Jul;
26(9):3897-3905.
PMID: 38951936
Aim: To perform a direct, double-blind, randomised, crossover comparison of subcutaneous and intravenous glucagon-like peptide-1 (GLP-1) in hyperglycaemic subjects with type 2 diabetes naïve to GLP-1-based therapy. Materials And Methods:...
8.
Abu Rached N, Dietrich J, Ocker L, Quast D, Scheel C, Gambichler T, et al.
J Clin Med
. 2023 Dec;
12(23).
PMID: 38068542
Hidradenitis suppurativa (HS) is a chronic skin disease that can have an association with endocrine disorders. There is conflicting information in the literature regarding the role of the thyroid gland...
9.
Overheu O, Lendowski S, Quast D, Kuhn D, Vidal Blanco E, Kraeft A, et al.
J Cancer Res Clin Oncol
. 2023 Jun;
149(12):10633-10644.
PMID: 37300723
Purpose: The SARS-CoV-2 Omicron variant of concern (VOC) and subvariants like BQ.1.1 demonstrate immune evasive potential. Little is known about the efficacy of booster vaccinations regarding this VOC and subvariants...
10.
Abu Rached N, Gambichler T, Ocker L, Dietrich J, Quast D, Sieger C, et al.
Int J Mol Sci
. 2023 Apr;
24(7).
PMID: 37047569
Hidradenitis suppurativa (HS) is a chronic skin disease that is often associated with metabolic disorders. Diabetes mellitus (DM) is a frequent comorbidity in HS. There is currently no established screening...